EFFECT OF SUGAMMADEX AND NEOSTIGMINE ON BLOOD GLUCOSE LEVEL: A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL

Yazar Akif Mehmet,1 Balaban Onur,2 Yoldas Kuvvet Tuba,3 Sarikus Zehra4

1 Konya Training and Research Hospital, Department of Anesthesiology, Konya, Turkey
2 Dumlupinar University, Department of Anesthesiology & Pain Medicine, Kutahya, Turkey
3 Ege University, Department of Anesthesiology, Izmir, Turkey
4 Nevsehir Public Hospital, Department of Anesthesiology, Nevsehir, Turkey

Abstract: Objectives: Sugammadex is offered as a recent alternative to cholinesterase inhibitors in reversing neuromuscular block. Sugammadex is a cyclodextrin molecule that is consisted of bounded sugar molecules. Given its chemical structure, sugammadex may increase blood glucose levels. We aimed to investigate the effect of sugammadex on blood glucose and compare sugammadex to the conventional reverse agent Neostigmine.

Methods: Sixty patients undergoing abdominal surgery under general anesthesia were included in this study. The patients were randomly divided into two groups: Group N (n = 30) and Group S (n = 30). At the end of the surgery 50 μg/kg Neostigmine and 20 μg/kg atropine was administered for the patients in Group N and 2 mg/kg sugammadex was administered for the patients in Group S. Blood glucose levels were measured at 15 minutes before (T1) and at 30th minute of surgery (T2). Blood glucose levels were recorded 30 minutes (T3), 2 hours (T4) and 4 hours (T5) after administration of the reversing agent.

Results: Blood glucose levels that were measured at T3, T4 and T5 were significantly higher in Group S compared to Group N (p < 0.05). We consider that sugammadex contains glucose molecules and does not bind to plasma proteins, may cause an increase in blood glucose level and this increase may be associated with chemical structure of sugammadex rather than surgical stress.

Key words: Neuromuscular block reverse, Sugammadex, Neostigmine, blood glucose level.

INTRODUCTION

Blood glucose level effects mortality and morbidity in the perioperative period. Surgical stimulus is among the most important factors that affect the metabolic and endocrine system response during surgery. Blood glucose level is increased by surgical stimulus that influences insulin and glucagon release. Increase in blood glucose levels is a factor that directly effects wound healing negatively and may prolong length of hospital stay (1, 2). Neuromuscular blocking agents are frequently used in general anesthesia in order to facilitate endotracheal intubation and provide muscle relaxation during the surgery. Non-depolarizing neuromuscular blockers, which are also known as muscle relaxants, block the binding of neurotransmitters to nicotinic acetylcholine receptor at the neuromuscular junction of motor neurons and paralyze the muscles. Cholinesterase inhibitors such as neostigmine are the most commonly used agents in anesthesiology practice to reverse effects of non-depolarizing neuromuscular blockers. Neostigmine provides acetylcholine accumulation in neuromuscular junction by inhibiting acetyl-cholin-esterase. This promotes neuromuscular transmission in the synapse and helps return of normal muscle function (3, 4, 5).

Sugammadex is an excellent alternative to the conventional decurarisation process performed with cholinesterase inhibitors. Sugammadex reverses deep rocuronium-induced neuromuscular block safely and rapidly without resulting in anticholinergic side effects. Sugammadex ensures elimination of non-depolarizing muscle relaxants such as rocuronium and vecuronium via the kidneys without being metabolized (6, 7, 8). Sugammadex is a modified gamma-cyclodextrin which makes steroidal non-depolarizing muscle relaxants inactive by encapsulating them. Gamma-cyclodextrin is consisted...
of eight glucose units. “Su” refers to sugar and “gammadex” refers to the structural molecule gamma-cyclodextrin (9, 10).

Our hypothesis was sugammadex might increase blood glucose levels given its chemical structure. We aimed to assess the effect of sugammadex on blood glucose and compare sugammadex to the conventional reverse agent Neostigmine.

MATERIAL AND METHODS

This study is designed as a prospective, randomized, controlled clinical research. It was approved by Clinical Research Ethics Committee of Kocaeli University. Written informed consents have been obtained from all patients that participated in the study. We enrolled 60 patients, aged between 18-65 years with American Society of Anesthesiologists (ASA) class I-II-III who were planned to undergo abdominal surgery under general anesthesia. The patients who had diabetes mellitus and other endocrine diseases (such as hyperthyroidism, hypothyroidism, renal-hepatic enzyme disorders, pregnancy and lactation) were excluded from the study. The patients were randomized into two groups using a computerized randomization program. Thirty patients were included in the Neostigmine group (Group N) and 30 patients were included in the sugammadex group (Group S).

All patients were held nil per os for 8 hours. After cannulation with 18-20 Gauge intravenous catheter, infusion of 0.9% normal saline was started. The patients did not receive any glucose-containing intravenous fluids and were not fed during the first 4 hours of the postoperative period. The patients were premedicated with 0.03 mg/kg midazolam and 1 μg/kg fentanyl before the surgery. Electrocardiography (ECG), heart rate (HR), non-invasive measurement of systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial blood pressure (MAP), pulse oxymetry (SpO2), and end-tidal carbon dioxide pressure (EtCO2) was monitored in the operating room. A train of four (TOF) device (Watch S, Organon) was used to measure the level of neuromuscular block. When maximum neuromuscular block was achieved (TOF ratio > 0.9), the patients were extubated after maximum muscle strength was achieved (TOF ratio > 0.9).

The blood glucose levels of the patients were measured using a glucometer (Optium®, Abbott laboratories, USA) with strip (Medisense®, Abbott laboratoires, UK). Blood glucose levels were measured 15 minutes preoperatively (T1) and at 30th minute intraoperatively (T2). Blood glucose levels were also recorded 30 minutes (T3), 2 hours (T4) and 4 hours (T5) after the administration of reverse agents. SAP, DAP, MAP, HR, SpO2, EtCO2 were recorded at the same time. Duration of surgery was also recorded which was defined as: “The time measured starting from the first incision of the skin until the end of closing sutures of the skin.”

Descriptive statistics (mean, standard deviation) were used to summarize data. Two-way analysis of variance (ANOVA) test was used for repeated measurements to find differences between the groups. Bonferroni paired t-test was used for repeated measurements and independent sample t-test was used for differences between the groups. Bonferroni paired t-test was used for paired comparisons within the groups. Independent sample t-test was used for the characteristics of the patients, and also Fisher’s exact test was used for nominal values. Statistical significance was considered as p < 0.05 in the two-tailed tests.

RESULTS

There were no statistically significant difference between the groups in terms of gender, age, weight, duration of surgery, ASA, and comorbid diseases (p > 0.05) (Table 1). The distribution of types of surgery in two groups was stated in Table 2.

Table 1. The characteristics of the patients

<table>
<thead>
<tr>
<th>Gender</th>
<th>Sugammadex (n = 30)</th>
<th>Neostigmine (n = 30)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>11/19</td>
<td>21/9</td>
<td>0.70 *</td>
</tr>
<tr>
<td>Female</td>
<td>19/11</td>
<td>9/11</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Sugammadex</th>
<th>Neostigmine</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>56.13 ± 8.38</td>
<td>52.20 ± 11.92</td>
<td>0.14 **</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Sugammadex</th>
<th>Neostigmine</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>69.57 ± 12.01</td>
<td>69.47 ± 12.71</td>
<td>0.97 **</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Duration of Surgery (min)</th>
<th>Sugammadex</th>
<th>Neostigmine</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>106.50 ± 31.89</td>
<td>98.83 ± 32.04</td>
<td>0.35 **</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ASA (I/II/III)</th>
<th>Sugammadex</th>
<th>Neostigmine</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>6/13/11</td>
<td>9/15/6</td>
<td>0.12 *</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Comorbid Disease (Yes/No)</th>
<th>Sugammadex</th>
<th>Neostigmine</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>22/8</td>
<td>15/15</td>
<td>0.06 *</td>
<td></td>
</tr>
</tbody>
</table>

*p: The two-tailed significance test, ASA: The American Society of Anesthesiologists Anesthesia Risk Scoring
When the blood glucose levels were compared between the groups, there was no significant difference at T1 and T2 between the two groups. Blood glucose levels were significantly higher at T3, T4 and T5 in the Sugammadex group compared to those in Neostigmine group (p < 0.05) (Figure 1). Blood glucose levels measured at T1, T2, T3, T4, T5 and p values in both groups were shown in Table 3. Heart rate, non-invasive measurement of systolic arterial pressure, diastolic arterial pressure, mean arterial blood pressure, oxygen saturation and end-tidal carbon dioxide pressure values were shown in Table 4.

DISCUSSION

The current study compared the effect of sugammadex on blood glucose levels to neostigmine in patients who underwent abdominal surgery. We determined a significant increase in glucose levels when sugammadex was used. Efficacy and safety of sugammadex was excessively studied before, but to our knowledge, there is no study showing the effect of sugammadex on perioperative blood glucose levels (11).

Table 2. Types of surgery performed in two groups

<table>
<thead>
<tr>
<th>Types of surgery</th>
<th>Sugammadex Group (n = 30)</th>
<th>Neostigmine Group (n = 30)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total abdominal hysterectomy and bilateral salpingo-oophorectomy</td>
<td>13</td>
<td>12</td>
</tr>
<tr>
<td>Excision of liver or pancreatic cysts</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Oophorectomy</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Exploration of abdominal masses</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Partial or total colectomy</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>Partial or total gastrectomy</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Myomectomy</td>
<td>0</td>
<td>2</td>
</tr>
</tbody>
</table>

Table 3. The blood glucose levels (mg/dL) in two groups

<table>
<thead>
<tr>
<th></th>
<th>Sugammadex Group</th>
<th>Neostigmine group</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>T1</td>
<td>105.77 ± 20.29</td>
<td>107.33 ± 14.14</td>
<td>0.742</td>
</tr>
<tr>
<td>T2</td>
<td>115.20 ± 15.05</td>
<td>111.87 ± 17.66</td>
<td>0.441</td>
</tr>
<tr>
<td>T3</td>
<td>146.20 ± 30.67</td>
<td>127.47 ± 23.00</td>
<td>0.008*</td>
</tr>
<tr>
<td>T4</td>
<td>143.03 ± 29.01</td>
<td>124.70 ± 22.57</td>
<td>0.007*</td>
</tr>
<tr>
<td>T5</td>
<td>141.37 ± 31.19</td>
<td>125.53 ± 27.27</td>
<td>0.034*</td>
</tr>
</tbody>
</table>

T1: 15 minutes preoperatively; T2: 30 minutes intraoperatively; T3: 30 minutes after administration of the reversing agent; T4: 2 hours after administration of the reversing agent; T5: 4 hours after administration of the reversing agent.

Table 4. The hemodynamic values measured in two groups

<table>
<thead>
<tr>
<th></th>
<th>T1</th>
<th>T2</th>
<th>T3</th>
<th>T4</th>
<th>T5</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAP (mm/Hg) mean ± SD</td>
<td>143.0 ± 23.59</td>
<td>120.57 ± 18.35</td>
<td>133.33 ± 22.74</td>
<td>138.47 ± 26.72</td>
<td>134.43 ± 24.09*</td>
</tr>
<tr>
<td>DAP (mm/Hg) mean ± SD</td>
<td>136.47 ± 26.85</td>
<td>126.73 ± 17.68</td>
<td>141.0 ± 18.95</td>
<td>123.23 ± 17.04</td>
<td>115.87 ± 17.16*</td>
</tr>
<tr>
<td>MAP (mm/Hg) mean ± SD</td>
<td>83.07 ± 16.97</td>
<td>69.77 ± 14.71</td>
<td>75.13 ± 12.33</td>
<td>78.73 ± 9.57</td>
<td>74.03 ± 8.63*</td>
</tr>
<tr>
<td>HR (beat/min) mean ± SD</td>
<td>98.2 ± 17.27</td>
<td>88.6 ± 14.28</td>
<td>104.13 ± 14.59</td>
<td>91.37 ± 14.61</td>
<td>84.13 ± 12.35*</td>
</tr>
</tbody>
</table>

SAP: Systolic arterial pressure; DAP: Diastolic arterial pressure; MAP: Mean arterial pressure; HR: Heart rate; N: Neostigmine; S: Sugammadex; SD: Standard deviation.

* p < 0.05 between the groups.
There are many factors that may influence blood glucose during and after a surgery. These factors include preoperative increased catabolic hormones due to dehydration, hunger, fear, perioperative bleeding, hypothermia, hypoxia, hypercapnia, pain, immobility, hypoxia, infection and circadian rhythm changes. The levels of adrenocorticotropic hormone and cortisol are elevated at the beginning of surgery, and then catecholamines, glucagon and growth hormone are released. Insulin secretion is reduced and insulin resistance often develops during surgical trauma (12, 13). Perioperative blood glucose level is elevated as a result of all of these reasons.

Sugammadex is the first selective neuromuscular relaxant drug binding agent, which is used to reverse the effects of non-depolarizing neuromuscular blockers. Decurarisation with sugammadex is a new approach to safely and rapidly reverse vecuronium or rocuronium-induced neuromuscular block. Sugammadex is a cyclodextrin and cyclodextrins contain 6-12 glucose units. Sugammadex does not bind to plasma proteins and erythrocytes. It does not produce any metabolite and is usually excreted unchanged with encapsulated neuromuscular blocker drug in urine within 24 hours. No major adverse effect of sugammadex was reported previously. Minor and common adverse effects reported include non-specific hypotension and cough at the end of the operation due to light anesthesia. Uncommon side effects are allergic reactions and return of muscle relaxation after the operation (14, 15, 16).

We hypothesized blood glucose level might increase due to the presence of free sugammadex in plasma and we noted a significant increase compared to neostigmine shortly after drug administration and after withdrawal of the endotracheal tube. This can be explained in two ways: stress response such as reaction to the endotracheal tube, agitation due to fast awakening as a result of the rapid reversal effect of sugammadex may be the reason of high blood glucose levels when sugammadex was used. In accordance with the literature, we considered that increase in blood glucose at early postoperative phase was associated with fast and efficient decurarisation provided by sugammadex (16-19). The second reason can be addressed as blood glucose levels are elevated due to the chemical structure of sugammadex. We evaluated blood glucose levels at 2 and 4 hours after extubation to distinguish between the two reasons. The blood glucose levels were significantly higher at 30th minute after extubation compared to glucose levels in the preoperative and intraoperative period in Sugammadex and Neostigmine groups. Thus, we considered increase of blood glucose at 30th minute after extubation may be associated with early postoperative stress. However, the blood glucose levels were also significantly higher 2 and 4 hours after endotracheal extubation in sugammadex-treated patients. We concluded that this situation was associated with the chemical structure of sugammadex.

The effect of sugammadex on blood glucose levels was studied among diabetic rats previously (20). Sugammadex was administered at different doses to control rats and diabetic rats. Serum glucose levels were found significantly higher in diabetic rats however there was no difference between diabetic rats that sugammadex was not given and sugammadex-treated diabetic rats. The effect of sugammadex on serum glucose has not been fully understood as expected because sugammadex-treated rats were diabetic. It is noteworthy that, reversal of neuromuscular block using sugammadex showed no difference in diabetic patients versus general population (21).

In conclusion, blood glucose levels were higher after administration of sugammadex compared to neostigmine in acute post-operative period. We consider that sugammadex contains glucose molecules and does not bind to plasma proteins may cause an increase in blood glucose level and this increase may be associated with chemical structure of sugammadex rather than surgical stress of patients.

DECLARATION OF INTEREST
The authors declare that there are no conflicts of interests.

Licensing
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.

Financial or grant support:
None.
Sažetak

**EFEKAT SUGAMADEKSA I NEOSTIGMINA NA NIVO GLUKOZE U KRVI: PROSPEKTIVNO RANDOMIZOVANO KONTROLISANO ISPITIVANJE**

Yazar Akif Mehmet,¹ Balaban Onur,² Yoldas Kuvvet Tuba,² Sarikus Zehra²

¹ Konya Training and Research Hospital, Department of Anesthesiology, Konya, Turkey
² Dumlupinar University, Department of Anesthesiology & Pain Medicine, Kutahya, Turkey
³ Ege University, Department of Anesthesiology, Izmir, Turkey
⁴ Nevsehir Public Hospital, Department of Anesthesiology, Nevsehir, Turkey

**Uvod:** Sugamadeks se koristi kao alternativa inhibitorima holinesteraze kod reverzibilnog neuromusku- 

larnog bloka. Sugamadeks je molekul ciklodeksstrina koji se sastoji od međusobno povezanih molekula se- 

ćera. Shodno hemijskoj strukturi, sugamadeks može pove- 

cati nivo glukoze u krvi. Cilj nam je bio da istražimo efekat sugamadeksa na nivo glukoze u krvi i uporedo-

minalnoj operaciji pod općom anestezijom, uključe-

no je u ovu studiju. Pacijenti su nasumično podeljeni u dve grupe: Grupa N (n = 30) i Grupa S (n = 30). Doza od 

50 μg/kg neostigmina i 20 μg/kg atropina je data paci-

jentima iz Grupe N, a 2 mg/kg sugamadeksa je data pa-

cijentima iz Grupe S. Nivo glukoze u krvi meren je 15 

minuta pre (T1) i 30og minuta operacije (T2). Nivo glu-

koze u krvi je takođe merena 30 minuta (T3), 2h (T4) i 

4h (T5) posle administracije reverzibilnog agensa.

**Rezultati:** Nivoi glukoze u krvi mereni u vreme-

nu T3, T4, T5 su bili značajno viši u Grupi S u poređe-

nju sa Grupom N (p < 0.05). Smatramo da sugamadeks koji sadrži molekule glukoze i ne vezuje se za proti-

ne plazme, može izazvati povećanje nivoa glukoze u krvi 

i ovo povećanje može biti povezano sa hemijskim 

strukturom sugamadeksa pre nego sa operacijom iza-

zanim stresom pacijenata.

**Ključne reči:** reverzibilni neuromuski blok, 

sugamadeks, neostigmin, nivo glukoze u krvi.

**REFERENCES**


11. Hristovska AM, Duch P, Allingstrup M, Afshari A. Ef-


16. Summary of product characteristics (Sugammadex) https://ec.europa.eu/health/documents/communityregi- 


17. WG, Heeringa M, et al. Effective reversal of moderate rocuroni-
um- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology. 2007; 106(2): 283-8.


Correspondence to/Autor za korespondenciju
Mehmet Akif Yazar M.D.
Department of Anesthesiology
Adress: Konya Training and Research Hospital, Department of Anesthesiology, Konya, Turkey.
Phone: +90 384 228 50 50
Mobil Phone: +90 505 566 57 58
E-mail: makifyazar@hotmail.com